Well that's the theory, but as we are no longer going to be informed of progressive dosing or recruitments, there could be long hiatuses intra- and inter-cohorts. Unless something deemed "material" is announced.
As far as we know there is no long line of prospective subjects in the waiting room, that has been the case so far and I think we just have to expect a longer time-frame than this. I would take this timetable kindly worked out for us (thanks) as a best case scenario.
Perhaps momentum will improve if early results are demonstrating efficacy.
BLT Price at posting:
81.5¢ Sentiment: Hold Disclosure: Held
